Biomarkers /
EGFR Exon 19 Deletion
Back to Biomarkers List
Overview
Biomarker-Directed Therapies
EGFR Exon 19 Deletion is a predictive biomarker for use of afatinib, erlotinib, gefitinib, osimertinib, capmatinib, crizotinib, dacomitinib, cetuximab, and pembrolizumab in patients.
Of the therapies with EGFR Exon 19 Deletion as a predictive biomarker, 6 are FDA-approved and 8 have NCCN guidelines in at least one clinical setting.
Non-small cell lung carcinoma has the most therapies targeted against EGFR Exon 19 Deletion or its related pathways [5].
Afatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) | |
| Note: Single agent (FDA, NCCN), or may be considered in combination with cetuximab after progression on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy (NCCN). |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) | |
| Note: Single agent or in combination with ramucirumab (FDA, NCCN), or in combination with bevacizumab (NCCN, non-squamous only). |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Preferred first-line therapy, per NCCN. Also approved as adjuvant therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Metastatic (MCG) | |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Metastatic (MCG) | |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
Pembrolizumab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with an EGFR or ALK alteration: FDA-approved as subsequent line of therapy following targeted therapy. However, per NCCN, data in the second-line setting suggest that subsequent pembrolizumab monotherapy is less effective in tumors with an EGFR mutation or ALK rearrangement. |
Afatinib + Capmatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Afatinib + Cetuximab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, may be considered after progression on on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy. |
Afatinib + Crizotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Clinical Trials
EGFR Exon 19 Deletion serves as an inclusion eligibility criterion in 205 clinical trials, of which 147 are open and 58 are closed. Of the trials that contain EGFR Exon 19 Deletion as an inclusion criterion, 1 is early phase 1 (0 open), 49 are phase 1 (29 open), 30 are phase 1/phase 2 (22 open), 88 are phase 2 (68 open), 5 are phase 2/phase 3 (4 open), 27 are phase 3 (22 open), 3 are phase 4 (1 open), and 2 are no phase specified (1 open).
Trials with EGFR Exon 19 Deletion in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, non-squamous non-small cell lung carcinoma, lung adenocarcinoma, squamous cell lung carcinoma, and malignant solid tumor [5].
Osimertinib, pembrolizumab, pemetrexed, carboplatin, and placebo are the most frequent therapies in trials with EGFR Exon 19 Deletion as an inclusion criteria [5].
Significance of EGFR Exon 19 Deletion in Diseases
Non-Small Cell Lung Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 181 clinical trials for non-small cell lung carcinoma, of which 127 are open and 54 are closed. Of the trials that contain EGFR Exon 19 Deletion and non-small cell lung carcinoma as inclusion criteria, 1 is early phase 1 (0 open), 44 are phase 1 (27 open), 29 are phase 1/phase 2 (21 open), 76 are phase 2 (56 open), 5 are phase 2/phase 3 (4 open), 21 are phase 3 (17 open), 3 are phase 4 (1 open), and 2 are no phase specified (1 open) [5].
Afatinib, gefitinib, erlotinib, crizotinib, osimertinib, dacomitinib, capmatinib, cetuximab, and pembrolizumab have evidence of efficacy in patients with EGFR Exon 19 Deletion in non-small cell lung carcinoma [5].
Malignant Solid Tumor +
EGFR Exon 19 Deletion is an inclusion criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain EGFR Exon 19 Deletion and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 6 are phase 2 (6 open) [5].
Non-Squamous Non-Small Cell Lung Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 9 clinical trials for non-squamous non-small cell lung carcinoma, of which 9 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 2 (3 open), and 4 are phase 3 (4 open) [5].
Lung Adenocarcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 8 clinical trials for lung adenocarcinoma, of which 6 are open and 2 are closed. Of the trials that contain EGFR Exon 19 Deletion and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 5 are phase 2 (5 open), and 2 are phase 3 (1 open) [5].
Breast Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 6 clinical trials for breast carcinoma, of which 6 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 3 are phase 2 (3 open) [5].
Melanoma +
EGFR Exon 19 Deletion is an inclusion criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].
Bladder Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].
Colorectal Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR Exon 19 Deletion and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].
Glioblastoma +
EGFR Exon 19 Deletion is an inclusion criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Head And Neck Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Head And Neck Squamous Cell Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Lung Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 2 clinical trials for lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR Exon 19 Deletion and lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].
Multiple Myeloma +
EGFR Exon 19 Deletion is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [5].
Pancreatic Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Small Cell Lung Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Squamous Cell Lung Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and squamous cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Urothelial Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Exon 19 Deletion and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Adenocarcinoma Of The Gastroesophageal Junction +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].
Anaplastic Astrocytoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].
B-Cell Non-Hodgkin Lymphoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bile Duct Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Biliary Tract Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bronchogenic Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cervical Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cervical Squamous Cell Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Endometrial Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Esophageal Squamous Cell Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gallbladder Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gastric Adenocarcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Hepatocellular Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
High Grade Ovarian Serous Adenocarcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Lymphoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Salivary Gland Neoplasm +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Supratentorial Neoplasm +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for malignant supratentorial neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and malignant supratentorial neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Uterine Neoplasm +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Mesothelioma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ovarian Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Pancreatic Adenocarcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Prostate Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Renal Cell Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Soft Tissue Sarcoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Thymic Carcinoma +
EGFR Exon 19 Deletion is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Exon 19 Deletion and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
